This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howe, A. Y. M.
Right arrow Articles by Del Vecchio, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howe, A. Y. M.
Right arrow Articles by Del Vecchio, A. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2006, p. 4103-4113, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00365-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Molecular Mechanism of a Thumb Domain Hepatitis C Virus Nonnucleoside RNA-Dependent RNA Polymerase Inhibitor{triangledown}

Anita Y. M. Howe,1* Huiming Cheng,1 Ian Thompson,1 Srinivas K. Chunduru,3,{dagger} Steve Herrmann,2 John O'Connell,1 Atul Agarwal,2,{ddagger} Rajiv Chopra,2 and Alfred M. Del Vecchio3,§

Infectious Diseases, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426,1 Biological Technology and Structural Biology, Wyeth Research, 85 Bolton Street, Cambridge, Massachusetts 02140,2 ViroPharma Incorporated, 405 Eagleview Boulevard, Exton, Pennsylvania 193413

Received 24 March 2006/ Returned for modification 26 May 2006/ Accepted 21 August 2006

A new pyranoindole class of small-molecule inhibitors was studied to understand viral resistance and elucidate the mechanism of inhibition in hepatitis C virus (HCV) replication. HCV replicon variants less susceptible to inhibition by the pyranoindoles were selected in Huh-7 hepatoma cells. Variant replicons contained clusters of mutations in the NS5B polymerase gene corresponding to the drug-binding pocket on the surface of the thumb domain identified by X-ray crystallography. An additional cluster of mutations present in part of a unique ß-hairpin loop was also identified. The mutations were characterized by using recombinant replicon variants engineered with the corresponding amino acid substitutions. A single mutation (L419M or M423V), located at the pyranoindole-binding site, resulted in an 8- to 10-fold more resistant replicon, while a combination mutant (T19P, M71V, A338V, M423V, A442T) showed a 17-fold increase in drug resistance. The results of a competition experiment with purified NS5B enzyme with GTP showed that the inhibitory activity of the pyranoindole inhibitor was not affected by GTP at concentrations up to 250 µM. Following de novo initiation, the presence of a pyranoindole inhibitor resulted in the accumulation of a five-nucleotide oligomer, with a concomitant decrease in higher-molecular-weight products. The results of these studies have confirmed that pyranoindoles target the NS5B polymerase through interactions at the thumb domain. This inhibition is independent of GTP concentrations and is likely mediated by an allosteric blockade introduced by the inhibitor during the transition to RNA elongation after the formation of an initiation complex.

* Corresponding author. Mailing address: Wyeth Research, 500 Arcola Road, Collegeville, PA 19426. Phone: (484) 865-2368. Fax: (484) 865-9401. E-mail: howeaym{at}wyeth.com.

{triangledown} Published ahead of print on 28 August 2006.

{dagger} Present address: TetraLogic Pharmaceuticals, 365 Phoenixville Pike, Malvern, PA 19355.

{ddagger} Present address: Centocor, Inc., 145 King of Prussia Road, Radnor, PA 19087.

§ Present address: Achillion Pharmaceutical Inc., 300 George Street, New Haven, CT 06511.

Antimicrobial Agents and Chemotherapy, December 2006, p. 4103-4113, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00365-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pawlotsky, J.-M. (2009). Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology 2: 205-219 [Abstract]  
  • Hang, J. Q., Yang, Y., Harris, S. F., Leveque, V., Whittington, H. J., Rajyaguru, S., Ao-Ieong, G., McCown, M. F., Wong, A., Giannetti, A. M., Le Pogam, S., Talamas, F., Cammack, N., Najera, I., Klumpp, K. (2009). Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus. J. Biol. Chem. 284: 15517-15529 [Abstract] [Full Text]  
  • Shi, S. T., Herlihy, K. J., Graham, J. P., Nonomiya, J., Rahavendran, S. V., Skor, H., Irvine, R., Binford, S., Tatlock, J., Li, H., Gonzalez, J., Linton, A., Patick, A. K., Lewis, C. (2009). Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother. 53: 2544-2552 [Abstract] [Full Text]  
  • Flint, M., Mullen, S., Deatly, A. M., Chen, W., Miller, L. Z., Ralston, R., Broom, C., Emini, E. A., Howe, A. Y. M. (2009). Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034). Antimicrob. Agents Chemother. 53: 401-411 [Abstract] [Full Text]  
  • Ali, S., Leveque, V., Le Pogam, S., Ma, H., Philipp, F., Inocencio, N., Smith, M., Alker, A., Kang, H., Najera, I., Klumpp, K., Symons, J., Cammack, N., Jiang, W.-R. (2008). Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479. Antimicrob. Agents Chemother. 52: 4356-4369 [Abstract] [Full Text]  
  • Herlihy, K. J., Graham, J. P., Kumpf, R., Patick, A. K., Duggal, R., Shi, S. T. (2008). Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors. Antimicrob. Agents Chemother. 52: 3523-3531 [Abstract] [Full Text]  
  • Howe, A. Y. M., Cheng, H., Johann, S., Mullen, S., Chunduru, S. K., Young, D. C., Bard, J., Chopra, R., Krishnamurthy, G., Mansour, T., O'Connell, J. (2008). Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796. Antimicrob. Agents Chemother. 52: 3327-3338 [Abstract] [Full Text]  
  • Chinnaswamy, S., Yarbrough, I., Palaninathan, S., Kumar, C. T. R., Vijayaraghavan, V., Demeler, B., Lemon, S. M., Sacchettini, J. C., Kao, C. C. (2008). A Locking Mechanism Regulates RNA Synthesis and Host Protein Interaction by the Hepatitis C Virus Polymerase. J. Biol. Chem. 283: 20535-20546 [Abstract] [Full Text]  
  • Shi, S. T., Herlihy, K. J., Graham, J. P., Fuhrman, S. A., Doan, C., Parge, H., Hickey, M., Gao, J., Yu, X., Chau, F., Gonzalez, J., Li, H., Lewis, C., Patick, A. K., Duggal, R. (2008). In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother. 52: 675-683 [Abstract] [Full Text]  
  • Zhou, Y., Bartels, D. J., Hanzelka, B. L., Muh, U., Wei, Y., Chu, H.-M., Tigges, A. M., Brennan, D. L., Rao, B. G., Swenson, L., Kwong, A. D., Lin, C. (2008). Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease. Antimicrob. Agents Chemother. 52: 110-120 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»